Numerous recent studies indicate that PIK3CA and downstream pathways are frequently targeted by genomic amplification, mutation or overexpression in solid tumors including ovarian cancer [12], [13], [14], [15], [16], [17], [18], [19], [20]. Here, PIK3CA is linked to ovarian carcinoma.